Expanded immune cells for CMV after stem cell transplant
Part of Infections clinical trials.
This trial tests a treatment using specially grown immune cells (virus-specific lymphocytes) to fight a stubborn CMV infection that hasn't gotten better with usual medicines. It is for people who have had a stem cell transplant and need help controlling CMV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You have had a stem cell transplant from a donor (like a sibling or cord blood).
- You have a serious CMV infection that is not responding well to standard antiviral medicines.
- You do not have severe graft-versus-host disease (GVHD).
- You are not pregnant or breastfeeding, and you agree to use birth control if applicable.
- You do not have an allergy to mouse proteins or iron-dextran.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
This trial tests whether adding specially trained immune cells (CTLs) from a related donor to standard treatment helps clear persistent adenovirus or CMV infections after a stem cell transplant. It may be an option if standard antiviral therapy isn't working or causes serious side effects.
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
Hear when a new CMV Viremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.